29 October
2020
Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).
Cathay International Holdings Limited
Total Voting Rights
In conformity with Rule 5.6.1 of the Disclosure Guidance and Transparency Rules, we notify the market that as at 28 October 2020 Cathay International Holdings Limited's capital consisted of 1,913,812,399 common shares of USD 0.01 each ("Common Shares") and 8,947,200 A shares of USD 0.01 each ("A Shares").
The A Shares and the Common Shares rank equally in all respects save that each A Share carries 20 votes and each Common Share carries one vote. A Shares are convertible into Common Shares on a one for one basis in accordance with the Bye-Laws of the Company.
Only the Common Shares are admitted to trading.
Accordingly, the total number of voting rights attached to the Common Shares is 1,913,812,399 and this figure should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Cathay International Holdings Limited under the Disclosure Guidance and Transparency Rules
-Ends-
For further enquiries, please contact:
|
Cathay International Holdings Limited
Eric Siu (Finance Director)
Patrick Sung (Director and Controller)
|
Tel: +852 2828 9289
|
|
SPARK Advisory Partners Limited (Financial Advisor)
Andrew Emmott / James Keeshan
|
Tel: +44 (0) 20 3368 3555
|
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People
'
s Republic of China (the
"
PRC
"
). The Company and its subsidiaries (collectively the
"
Group
"
) aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.
The Group employs approximately
1,300
people across the PRC, including over
2
0 specialist corporate and business development staff based at the holding
c
ompany
'
s offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company
'
s website:
www.cathay-intl.com.hk
.
